Table 4.
Adjusted † odds ratios (OR) for histological progression or regression with high Epstein–Barr virus (EBV) antibody titers, by baseline histological diagnosis
| Progression during follow up | |||
|---|---|---|---|
| SG/CAG or IM (n = 116) | SG/CAG only (n = 55) | IM only (n = 61) | |
| OR (95% CI) | OR (95% CI) | OR (95% CI) | |
| EBNA ≥1:320 | 2.8 (1.1–6.8) | 1.2 (0.3–4.6) | 5.7 (1.6–20) |
| VCA ≥1:640 | 1.5 (0.6–3.9) | 0.5 (0.1–2.3) | 3.8 (1.0–15) |
| Regression during follow up | |||
|---|---|---|---|
| IM or DYS (n = 104) | IM only (n = 61) | DYS only (n = 43) | |
| OR (95% CI) | OR (95% CI) | OR (95% CI) | |
| EBNA ≥1:320 | 0.7 (0.3–1.7) | 0.4 (0.1–2.1) | 0.8 (0.2–2.9) |
| VCA ≥1:640 | 0.7 (0.3–1.7) | 0.5 (0.1–2.5) | 0.9 (0.2–3.7) |
†
OR adjusted for age, sex and cohort membership.
DYS, dysplasia; EBNA, Epstein–Barr virus nuclear antigen; IM, intestinal metaplasia; SG/CAG, superficial gastritis or chronic atrophic gastritis; VCA, viral capsid antigen.